De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Insmed Beheer

Beheer criteriumcontroles 3/4

De CEO Insmed's is Will Lewis, benoemd in Sep2012, heeft een ambtstermijn van 12.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.41M, bestaande uit 7.5% salaris en 92.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde $ 32.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.9 jaar en 10.4 jaar.

Belangrijke informatie

Will Lewis

Algemeen directeur

US$10.4m

Totale compensatie

Percentage CEO-salaris	7.5%
Dienstverband CEO	12.1yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	10.4yrs

Recente managementupdates

Recent updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

Dec 18

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Jul 28

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jul 01

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Apr 18

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Feb 23

Insmed inks financing agreements to raise $500M

Oct 19

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24

Analyse CEO-vergoeding

Hoe is Will Lewis's beloning veranderd ten opzichte van Insmed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$803m
Mar 31 2024	n/a	n/a	-US$747m
Dec 31 2023	US$10m	US$780k	-US$750m
Sep 30 2023	n/a	n/a	-US$724m
Jun 30 2023	n/a	n/a	-US$696m
Mar 31 2023	n/a	n/a	-US$547m
Dec 31 2022	US$8m	US$735k	-US$482m
Sep 30 2022	n/a	n/a	-US$434m
Jun 30 2022	n/a	n/a	-US$416m
Mar 31 2022	n/a	n/a	-US$438m
Dec 31 2021	US$7m	US$710k	-US$435m
Sep 30 2021	n/a	n/a	-US$424m
Jun 30 2021	n/a	n/a	-US$375m
Mar 31 2021	n/a	n/a	-US$319m
Dec 31 2020	US$6m	US$660k	-US$294m
Sep 30 2020	n/a	n/a	-US$245m
Jun 30 2020	n/a	n/a	-US$242m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$7m	US$641k	-US$254m
Sep 30 2019	n/a	n/a	-US$293m
Jun 30 2019	n/a	n/a	-US$320m
Mar 31 2019	n/a	n/a	-US$330m
Dec 31 2018	US$6m	US$610k	-US$324m
Sep 30 2018	n/a	n/a	-US$298m
Jun 30 2018	n/a	n/a	-US$256m
Mar 31 2018	n/a	n/a	-US$224m
Dec 31 2017	US$4m	US$567k	-US$193m

Compensatie versus markt: De totale vergoeding ($USD 10.41M ) Will } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).

Compensatie versus inkomsten: De vergoeding van Will is gestegen terwijl het bedrijf verliesgevend is.

CEO

Will Lewis (55 yo)

12.1yrs

Tenure

US$10,411,260

Compensatie

Mr. William H. Lewis, also known as Will, J.D. M.B.A. serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	12.1yrs	US$10.41m	0.26% $ 32.8m
Sara Bonstein	Chief Financial Officer	4.8yrs	US$4.56m	0.011% $ 1.3m
Roger Adsett	Chief Operating Officer	4.9yrs	US$4.01m	0.037% $ 4.6m
John Wise	Chief Commercial Officer	4.9yrs	US$3.89m	0.030% $ 3.8m
Martina Flammer	Chief Medical Officer	4.8yrs	US$4.22m	0.0074% $ 927.3k
Brian Kaspar	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Eleanor Barisser	Associate Director of Investor Relations	no data	geen gegevens	geen gegevens
Michael Smith	Chief Legal Officer & Corporate Secretary	3.3yrs	geen gegevens	0.039% $ 5.0m
Mandy Fahey	Executive Director of Corporate Communications	no data	geen gegevens	geen gegevens
S. Schaeffer	Chief People Strategy Officer	11.8yrs	US$2.66m	0.020% $ 2.5m
Eugene Sullivan	Chief Product Strategy Officer	7.4yrs	US$1.69m	geen gegevens
Neil Hughes	GM & Head of Europe	5.3yrs	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INSM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Lewis	President	12.1yrs	US$10.41m	0.26% $ 32.8m
David W. McGirr	Independent Director	11yrs	US$320.00k	0.050% $ 6.3m
Melvin Sharoky	Independent Director	23.4yrs	US$312.50k	0.19% $ 23.7m
Alfred Altomari	Independent Director	12.2yrs	US$320.00k	0.033% $ 4.1m
David Brennan	Lead Independent Director	10.4yrs	US$345.00k	0.063% $ 7.9m
Clarissa Desjardins	Independent Director	4.9yrs	US$315.00k	0.028% $ 3.6m
Elizabeth Anderson	Independent Director	5.9yrs	US$310.00k	0.032% $ 4.1m
Leo Lee	Independent Director	6.4yrs	US$317.50k	0.065% $ 8.1m
Carol Schafer	Independent Director	4.5yrs	US$315.00k	0.026% $ 3.3m

10.4yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INSM zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.4 jaar).

Insmed Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Chief Medical Officer notifies of intention to sell stock

Chief People Strategy Officer recently sold US$686k worth of stock

Insider notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$768k worth of stock

Chief Financial Officer notifies of intention to sell stock

President recently sold US$566k worth of stock

Recent updates

Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up

Chief Medical Officer notifies of intention to sell stock

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Chief People Strategy Officer recently sold US$686k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Insider notifies of intention to sell stock

Is Insmed (NASDAQ:INSM) A Risky Investment?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 8.7% to US$82.63

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Price target increased by 7.0% to US$73.44

Chief Medical Officer exercised options and sold US$768k worth of stock

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Chief Financial Officer notifies of intention to sell stock

Price target increased by 25% to US$56.56

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

Insmed Incorporated Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

New major risk - Share price stability

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

President recently sold US$566k worth of stock

President notifies of intention to sell stock

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed inks financing agreements to raise $500M

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022